Goldstein Dan 4

4 · HAEMONETICS CORP · Filed May 18, 2022

Form 4

Period: 2022-05-16

Chief Accounting Officer

Transactions

Sale
Common Stock
2022-05-16$56.10/sh−50$2,805→ 4,004 total
Award
Non-qualified Stock Option (Right to Buy)
2022-05-16+2,029→ 2,029 total
Exercise: $57.60Exp: 2029-05-16→ Common Stock (2,029 underlying)
Award
Common Stock
2022-05-16+868→ 4,872 total

Footnotes (5)

[F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
[F2]This number includes unvested RSUs previously reported.
[F3]The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
[F4]Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
[F5]Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Documents

1 file